Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440518 · ClinicalTrials.gov registry record · Phase 2
A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis
A Phase 2 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
NCT00440518 is a Phase 2 study that has completed, run by UCB Pharma. The registered enrollment target is 218 participants.
The verdict
NCT00440518, a Phase 2 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
Study Summary
The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.
Interventions
- OTHER Placebo
- DRUG Lacosamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2007-02 |
| Est. Completion | 2008-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00440518
The ClinicalTrials.gov registry entry for NCT00440518 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00440518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00440518 about?
NCT00440518 is a clinical study titled "A Study Designed to Test the Effectiveness and Safety of Treating Patients With Lacosamide for Migraine Prophylaxis". The purpose of this study is to see how safe and effective Lacosamide (LCM) is when taken by mouth, twice a day for up to 18 weeks to prevent migraines.
What is the current status of trial NCT00440518?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2007-02. Estimated completion is 2008-07.
What interventions are being tested in trial NCT00440518?
The interventions under investigation include: Placebo (OTHER), Lacosamide (DRUG).
Who is sponsoring clinical trial NCT00440518?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.